Drug firm Lupin on Tuesday said it has launched generic Divalproex Sodium extended-release tablets used for treatment of various conditions, including manic episodes associated with bipolar disorder, in the American market.
The company has launched Divalproex Sodium extended-release (ER) tablets USP, in the strengths of 250 mg and 500 mg, having received an approval earlier from the United States Food and Drug Administration (USFDA), Lupin said in a statement.
The product will be manufactured at the company's Nagpur facility, it added.
The company's tablet is generic version of AbbVie Inc's Depakote extended-release tablets in the same strengths, Lupin said.
According to IQVIA MAT July 2020 data, Divalproex Sodium extended-release tablets USP had annual sales of approximately USD 130 million (about Rs 950 crore) in the US, it added.
The tablets are indicated for acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features, and for prophylaxis of migraine headaches, the statement said.
The product is also indicated for monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures, adjunctive therapy in patients with multiple seizure types that include absence seizures, it added.
Shares of Lupin Ltd on Tuesday closed 0.07 per cent lower at Rs1,040per scrip on the BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU